Search This Blog

Wednesday, October 1, 2025

UnitedHealth, CVS Health, Humana scale back Medicare Advantage offerings

 A confluence of factors is leading to a significant shake-up in the Medicare Advantage landscape in 2025. Key elements include the redesign of the Part D benefit due to regulatory changes included in the Inflation Reduction Act, lower-than-expected benchmark rates, the transition to the v28 Risk Adjustment model, and rising medical trends. These warning signs about the financial sustainability of benefit-rich Medicare Advantage plans have prompted several insurers to pull back in 2025, resulting in product closures and exits from markets. Despite these disruptions, consumers will still have a broad range of choices and can shop for alternative products.

Decisions around 2025 offerings notwithstanding, insurers must take a hard look at their Medicare Advantage strategy if they are going to ensure long-term viability. We highlighted a few key factors in this previous Oliver Wyman Health article.

Plan Exits and Closures

More than 1.8 million Medicare Advantage members are enrolled 2024 plans that will not be offered in 2025. A few things jump out from the data:

  • Approximately 1.3 million of these members are enrolled in PPO plans, representing 70% of those affected by plan exits
  • Humana, CVS Aetna, and UnitedHealthcare collectively impact over 1.2 million members due to their plan closures
  • Eighteen marketing brands — including Premera Blue Cross and Blue Cross and Blue Shield of Kansas City — are exiting the market entirely in 2025, affecting tens of thousands of members

Major Enrollment Impacts from Product Closures from National, For-Profit Carriers

Exhibit 1: Plan closures across three companies are causing the most disruption
Notes: Includes individuals in non-SNP, non-Group plans
Source: CMS, Oliver Wyman analysis

The loss of plans offered by Humana, CVS Aetna, and UnitedHealthcare leaves a large hole to fill. Humana will have the most significant impact on its members, with over 500,000 of 2024 members enrolled in products that will be closed in 2025. CVS Aetna follows closely, with an estimated 450,000 members affected, and UnitedHealthcare ranks third, with over 250,000 members enrolled in products that will not be offered in 2025.

It's important to highlight that these plan exits reflect members who will not be automatically moved into other products, even if one was available. While these plan exits may seem alarming, carriers in many of these markets have introduced new products or have other products that members can switch to for 2025. This will enable members affected by the plan closures to potentially choose alternative options within the carrier’s portfolio. However, this still results in disruptions to members' experience and continuity of coverage, and the risk that these members will switch to other carriers.

Consumer-Facing MA Brands Exiting the Medicare Advantage Market Entirely

A total of 18 marketing organizations announced their departure from Medicare Advantage. Notable exits include Premera Blue Cross, affecting over 30,000 members in Washington, and Blue Cross and Blue Shield of Kansas City, impacting a similar number in Missouri and Kansas. Additionally, Harvard Pilgrim Healthcare’s exit will affect over 10,000 members. Despite these closures, the overall impact on the market is expected to remain minimal, with brand exits accounting for less than 1% of total enrollment, approximately 150,000 members. For some of these brands, the parent organization remains in the market under a different marketing name, so the closure is more of a member-facing brand impact than true-scale plan exit.

Disproportionate Exits of PPO Plans

Members enrolled in PPO plans will be more significantly affected than those in HMO/HMO-POS plans, with approximately 1.3 million members (70%) in PPO plans in 2024 enrolled in products that will not be offered in 2025 — and not crosswalked — compared to around 530,000 members (30%) in HMO plans.

Diving into this further, organizations have made specific decisions to eliminate their PPO plan options in certain states and counties. This reflects a broader trend among insurers that are reassessing product offerings and adjusting service areas. Organizations have made surgical decisions to eliminate their PPO plan options in specific states and counties.

For example, of the approximately 250,000 members that will be impacted by UnitedHealthcare’s plan closures in 2025, about 185,000 were in PPO plans in 2024. Around 30,000 of these 185,000 members — about 15% — will have no alternative PPO options in their county because UnitedHealthcare is exiting its PPO plans in 38 counties. For the 85% of members, other UnitedHealthcare PPO options will be available in the counties, but they were not crosswalked.

Organizations have not removed their HMO plans to the same extent. Notable HMO exits include Humana leaving Delaware and South Dakota and CVS exiting Idaho. Centene has also made smaller exits from states like Alabama and Massachusetts, but these changes are far less widespread than those affecting PPO plans.

The closure and exit of more PPO plans compared to HMO plans for 2025 could be driven by financial viability issues, as PPOs tend to have higher costs, with plans that are harder to manage and ensure quality, and overall, less predictable revenue streams.

Keeping a Close Eye on Member Movement

It’s critical that insurers watch how plan switching, and consumer shopping behavior is impacted by this disruption. Will some consumers exit Medicare Advantage entirely? What strategies — if any — will remaining carriers implement to attract members from exiting plans, particularly in the PPO segment? Will the remaining plans end up exceeding growth targets by virtue of being in a market that other brands exited? And how will that impact their business?

We expect this to be the beginning of a two-to-three-year disruption cycle and plans will continue to make significant changes to their product portfolio and service areas in 2026 — especially as we see how the annual enrollment period and 2025 plan profitability shape up.

https://www.oliverwyman.com/our-expertise/perspectives/health/2024/oct/plan-exits-cause-shakeup-in-medicare-advantage-offerings.html

UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight

 

Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.

The U.K. life sciences sector was rocked by a series of major blows in September. In a matter of days, Merck pulled out of a $1.3 billion project and AstraZeneca—a U.K.-based firm—paused plans to invest around $270 million in an R&D site. Sanofi and Eli Lilly similarly pulled back on investment plans for the country. The quadruple whammy brought long-festering tensions between pharma and the government into the open and raised doubts about the U.K.’s place in the global life sciences industry.

AstraZeneca and Merck revealed the changes to their U.K. spending plans weeks after drug pricing talks between the pharma industry and government collapsed. A Parliament committee held in response to the changes shed light on the situation. Tom Keith-Roach, U.K. president at AstraZeneca, said problems have been “building and accumulating over the last 20 years” as the country has become an increasingly challenging place to launch drugs. Those problems are now influencing where companies invest.

“What we are increasingly seeing is discretionary investment and new investment in R&D and in capital manufacturing is flowing into countries who are seen to value innovation and seem motivated to pull that through into patients,” Keith-Roach said at the hearing.

Pharma no longer sees the U.K. as such a viable option. The question now is whether the U.K. government can change the narrative and save an industry that it recently called “one of our greatest national assets.”

Why the UK Lost Credibility

The recently collapsed talks between the U.K. government and pharma focused on the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). Through VPAG, drugmakers provide rebates to cover government spending on branded medicines above a certain threshold. The current rate is higher than expected, leading the industry and government to pull forward a mid-scheme review.

Keith-Roach and Richard Torbett, CEO of the Association of the British Pharmaceutical Industry (ABPI), both used the Parliament committee meeting to warn the government that the industry wants more than just a resolution to the VPAG impasse. To Keith-Roach, VPAG is “a symptom of the problem rather than the cause.”

“We can negotiate about VPAG, but in the long term, this needs to be a country that is committed to investing in innovation, to making innovation available to patients and to providing a front door to the NHS through which innovative medicines can pass,” Keith-Roach said.

Torbett said the government needs to fix VPAG, change the threshold the U.K. uses for cost-effectiveness and provide a sustained commitment to bringing investment up to the level of comparable countries. At the committee, Lord Patrick Vallance, the former GSK executive who now serves as Minister for Science, Innovation, Research and Nuclear, showed that the government knows the problem goes beyond VPAG. “The real crunch issue is the appropriate uptake, access and payment on medicines,” Vallance said.

As part of its attempt to fix the issue, the government proposed putting £1 billion (roughly $1.35 billion) into the market over three years. However, with the industry calculating it would still need to pay back £13.5 billion (more than $18 billion), talks collapsed without an agreement being reached.

The collapse of the drug pricing negotiations came months after U.K. Prime Minister Keir Starmer reportedly said he would “sort the VPAG” in a meeting with pharma CEOs. Starmer’s failure so far to follow through on that commitment has added to doubts about the government’s capacity to back up talk with action.

“I might categorize it as a credibility challenge,” Ben Lucas, managing director for the U.K. and Ireland at Merck, told the committee. “We have been having this continued conversation with successive governments about the potential of the U.K. to be able to pull down and realize—in an economic growth way—the talent that it has. But we failed, and that has been a collective failure across the board.”

The failures have colored how overseas pharma executives see the U.K. Lucas, who works with Merck’s U.S.-based executive team, said, “The challenge I continually get is, ‘Well, we’ve heard that plan before, Ben, but it hasn’t necessarily delivered.’”

Where Investment Is Going

Other countries are capitalizing on the U.K.’s failure to deliver change. Torbett said the U.K. is losing out to a variety of countries, including the U.S., Belgium, Ireland, Singapore and Germany. ABPI has “lots of examples of decisions that have been in the balance, and those are the sorts of countries that we have lost out to,” Torbett said.

The losses are adding up. Sanofi, which recently froze investment in the U.K., has reduced its headcount in the country from more than 2,000 in 2013 to below 600 today. Over a similar period, the headcount at Sanofi’s Genzyme Ireland unit has grown from 477 to 905. The shifts have added to the pressure on the government to retain AstraZeneca and GSK, the other U.K.-based multinational. Each of these two pharma powerhouses employ close to 10,000 people in the U.K.

“We cannot afford to lose this industry from the U.K.,” Vallance said. “It is very important that we have two global companies; it matters that it is two. It is very important that we have a very thriving startup and SME sector here as well, and that is not only important for the economy; it is important for health. We must come to an agreement on the right way forward.”

https://www.biospace.com/drug-development/how-the-uks-credibility-challenge-hinder-attempts-to-reverse-pharmas-flight

Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’

 

Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.

Novo Nordisk has turned its back on cell therapy specialist Heartseed, terminating a four-year-old contract amid a broader strategic realignment.

Tokyo-based Heartseed announced the termination of the partnership in a securities filing on Tuesday, noting that Novo’s decision was driven by its push to “further concentrate on its core business areas of diabetes and obesity.” It is not clear when the agreement will formally end, but Heartseed will no longer be eligible for milestone payments when that date does come.

“We applaud CEO Mike Doustdar’s decisive restructuring and strategy shift,” analysts at BMO Capital Markets told investors in a note Tuesday evening, though they weren’t explicitly reacting to the Heartseed termination. “After witnessing the boon and subsequent fall of NVO shares, we’re starting to see green shoots of a new, refined, and refocused strategy.”

Novo and Heartseed linked up in June 2021, with Novo putting down $55 million in upfront and near-term payments to collaborate on the biotech’s lead asset HS-001, an investigational cell therapy for heart failure. Novo also put more than $540 million on the line in milestone commitments.

In exchange for its investments, Novo gained the exclusive right to advance, manufacture and commercialize HS-001 outside Japan, giving Heartseed the chance to earn high-single-digit to low-double-digit royalties on net sales. The biotech retained development rights to the asset in Japan.

Following the deal’s termination, all intellectual property related to HS-001 will return to Heartseed, which will now “explore options including partnerships” for the overseas development of the asset, according to Heartseed’s securities filing. While the biotech reviews its overseas strategy, it will focus its efforts on HS-001’s Japanese development. “For the time being, we have the resources to continue development as planned using our existing funds,” Heartseed wrote.

The decision to break off the Heartseed pact comes in the thick of Novo’s sweeping and aggressive restructuring initiative. Shares of the pharma are down 35% year-to-date and Novo recently completed a high-profile executive shuffle: In May, former CEO Lars Fruergaard Jørgensen stepped down from his post and was replaced by Doustdar, who had previously served as the company’s executive vice president of international operations.

During Novo’s Q2 earnings call, where Doustdar had the opportunity to address investors before he formally assumed the CEO role, he said he would focus on execution and promised to trim the fat. “We need to reallocate and look at our cost base and really put the money where the growth is,” he said, in order to “not fall behind the competition.” Earlier this month, Novo announced it would be laying off 9,000 employees worldwide.

https://www.biospace.com/business/novo-breaks-598m-heartseed-pact-amid-decisive-restructuring-by-new-ceo

Reddit Plunges On New Traffic Data Suggesting ChatGPT "Massively Reduced Citations"

 Reddit shares are sinking in New York premarket trading, and if the losses hold into the cash session, it would mark the steepest decline in six months. The drop comes after new Similarweb data indicated that ChatGPT has either scaled back or completely stopped using Reddit as a source for answer generation. Who would have ever guessed that relying on Reddit posts to generate chatbot answers was a brilliant idea?

Several X users are citing Similarweb data that shows Reddit's collapsing web traffic. This includes one X user by the name of "Bert Tian" who states:

$RDDT US Website DAU (source @Similarweb ) has dropped sharply after ChatGPT massively reduced Reddit citations — traffic is now even close to early-year levels.

Multiple data vendors are all picking up the shift in ChatGPT citation patterns. Reasons still unclear, but one guess is that ChatGPT may be limiting web search for free accounts as a cost-cutting move to push monetization.

Tian posted an image showing Reddit's U.S. daily active users on a 30-day average, indicating that around September 11 was the point when Reddit sources cited by ChatGPT dropped sharply.

Source: X user Bert Tian

Tian was quoting another X user by the name of "Andrea Bosoni," who pointed out:

Apparently ChatGPT is not using Reddit much anymore for their answers. I guess they realized that what random people say can't be considered a trusted source after all. You can all stop spamming it with your fake brand mentions now.

Source: Andrea Bosoni

TryProfound blog cited a dataset between August 2024 and June 2025 that showed Reddit accounts for 11.3% of ChatGPT's citations within its top 10 most-cited sources.

Source: TryProfound

Reddit shares dropped as much as 13% in premarket trading. If losses hold through the cash session, this would mark the largest decline since early March.

So, ChatGPT relies heavily on Wikipedia and Reddit… enough said. That's why Elon Musk revealed on Tuesday his plans to launch "Grokpedia."

https://www.zerohedge.com/markets/reddit-plunges-new-traffic-data-suggesting-chatgpt-massively-reduced-citations

DEA Arrests 670, Seizes Nearly 77,000 Kilograms Of Drugs in NY In Operation Targeting Notorious Cartel

 by Travis Gillmore via The Epoch Times (emphasis ours),

The Drug Enforcement Administration (DEA) arrested 670 individuals and seized nearly 77,000 kilograms of narcotics during a five-day operation targeting a Mexican drug trafficking organization, according to an agency statement on Sept. 29.

Drug Enforcement Administration agents seized nearly 77,000 kilograms of illegal drugs during a weeklong operation targeting the Jalisco New Generation Cartel, the agency announced on Sept. 29, 2025. Courtesy of Drug Enforcement Agency

Agents sought to dismantle the Jalisco New Generation Cartel, designated as a foreign terrorist organization in February with an executive order from President Donald Trump for its role in orchestrating illegal drug distribution.

Let this serve as a warning: DEA will not relent,” agency administrator Terrance Cole said in a statement.

Every arrest, every seizure, and every dollar stripped from [the cartel] represents lives saved and communities protected. This focused operation is only the beginning—we will carry this fight forward together until this threat is defeated.”

The cartel operates across the globe in at least 40 countries, with tens of thousands of individuals helping produce, manufacture, and distribute dangerous narcotics, according to the DEA.

Cole said the operation, which ran from Sept. 22 through Sept. 26, involved collaboration between DEA agents in 23 domestic and seven foreign divisions, a Department of Homeland Security Task Force, other federal agencies, and state and local law enforcement partners.

Investigations led to the seizure of nearly 100 kilograms of fentanyl—enough to kill about 50 million people, by the agency’s calculations.

More than 1.1 million counterfeit pills were seized, along with more than 6,000 kilograms of methamphetamine, almost 23,000 kilograms of cocaine, and 33 kilograms of heroin.

Photos from the agency’s Atlanta office show tables piled high with confiscated packages filled with seized narcotics. Another image shows roughly 300,000 counterfeit pills, pressed in a variety of colors, seized in New York.

Approximately $19 million in cash and currency was recovered, and the agency estimated the value of assets impounded at nearly $30 million.

Also confiscated were 244 firearms, officials said.

Hundreds of cartel members and associates were detained, but the group’s leaders have eluded capture.

The U.S. Department of State is offering a $15 million reward for information that leads to the apprehension of co-founder Nemesio Rubén Oseguera Cervantes, known as El Mencho.

Oseguera Cervantes was indicted in the United States in 2017, and again subsequently on multiple occasions, for conspiracy to commit drug trafficking crimes.

According to the State Department, he has also allegedly been involved in assassination attempts on Mexican government officials.

Drug Enforcement Administration agents display approximately 300,000 counterfeit pills seized in an operation targeting the Jalisco New Generation Cartel in September 2025. Courtesy/Drug Enforcement Administration

Among other groups that have been designated foreign terrorist organizations by the federal government are the Noreste cartel—previously known as Las Zetas—the Sinaloa cartel, Tren de Aragua, and Mara Salvatrucha, better known as MS-13.

The terrorist designations “expose and isolate” suspects and provide law enforcement with more leverage to investigate and disrupt transnational criminal networks, according to the State Department.

https://www.zerohedge.com/geopolitical/dea-arrests-670-seizes-nearly-77000-kilograms-drugs-operation-targeting-notorious

 The British government has issued a new order to Apple to create a backdoor into its cloud storage service, this time targeting only British users' data, the Financial Times reported on Wednesday.

Britain dropped a mandate for the iPhone maker to provide a backdoor that would have enabled access to the protected encrypted data of American as well as British citizens, U.S. Director of National Intelligence Tulsi Gabbard said in August.

U.S. lawmakers had raised concerns that such a move could allow encrypted user data to be exploited by cyber criminals and authoritarian governments.

The feature allows iPhone and Mac users to ensure that only they — and not even Apple — can unlock data stored on its cloud.

"Apple is still unable to offer Advanced Data Protection (ADP) in the United Kingdom to new users, and current UK users will eventually need to disable this security feature," Apple said on Wednesday.

"ADP protects iCloud data with end-to-end encryption, which means the data can only be decrypted by the user who owns it, and only on their trusted devices."


The company said it was committed to offering users the highest level of security and it was hopeful it would be able to do so in the future in Britain.

"As we have said many times before, we have never built a backdoor or master key to any of our products or services and we never will," it added.

GOP leaders blame ‘Schumer Shutdown’ on top Senate Dem’s caving to ‘far-left activist groups’

 Senate Majority Leader John Thune (R-SD) at the same presser accused his Democratic counterpart of having shut down the government "at the behest of a bunch of liberal, far-left activist groups."

Senate Majority Leader John Thune (R-SD) (C) leads a news conference with Speaker of the House Mike Johnson (R-LA) (C-L) and House and Senate GOP Leadership on the Upper West Terrace of U.S. Capitol Building on October 1, 2025 in Washington, DC.
The "government shutdown that the Democrats wanted," Senate Majority Leader John Thune (center) said.Getty Images

The "government shutdown that the Democrats wanted," Thune added, has put their party "into a box canyon."

Three Democrats joined 52 Senate Republicans to vote to keep the government open before the federal shutdown started at 12:01 a.m. Wednesday.

Senate Minority Leader Chuck Schumer, D-N.Y., attends a news conference about the government shutdown, Tuesday, Sept. 30, 2025, on Capitol Hill in Washington.
Senate Minority Leader Chuck Schumer led the opposition.AP

Senate Minority Leader Chuck Schumer (D-NY) led the opposition to the funding bill, in part because it didn't extend Obamacare subsidies that expire at the end of this year.


https://nypost.com/2025/10/01/us-news/trump-live-updates-news-oct-1-2/